Astellas Pharma Inc. provided impairment loss for intangible assets guidance for the fourth quarter 2023. Booking and details of impairment loss for intangible assets (estimated amount): As a result of reevaluation of the intangible asset for AT808 for the treatment of Friedreich's Ataxia, Astellas will book an impairment loss for intangible assets of approximately ¥40.0 billion related to AT808 as other expenses. As a result of a review of plans for EVRENZOTM for the treatment of anemia of chronic kidney disease sold in Japan and Europe, considering the sales situation in each country, Astellas will book an impairment loss for intangible assets of approximately ¥16.0 billion related to EVRENZOTM as other expenses.